Bavarian Nordic Secures Major Mpox/Smallpox Vaccine Deal in Europe

Bavarian Nordic has confirmed a substantial new contract to supply its MVA‑BN® smallpox/mpox vaccine to an undisclosed European nation, strengthening the region’s readiness against biological threats. The recurring order, part of Europe’s growing focus on public health security, is valued at over DKK 200 million. With this latest agreement alongside other global deals, Bavarian Nordic has now secured over DKK 3 billion (approx. USD 400 million) in public preparedness contracts for 2025, meeting its full-year guidance.

Paul Chaplin, CEO of Bavarian Nordic, stated the deal underscores Europe’s commitment to vaccine preparedness amid evolving geopolitical risks. The MVA‑BN® vaccine, already approved in the U.S. and EU, continues to be a cornerstone of government immunisation strategies. In addition to this contract, the company is progressing with clinical trials aimed at expanding use to infants and pregnant women, and advancing its chikungunya vaccine pipeline in Europe and the U.K.

Bavarian Nordic's strong performance in vaccine supply and development reflects its broader mission to safeguard public health through innovation and global partnerships.